Compare Eli Lilly And Co (LLY) vs Prologis Inc (PLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Prologis Inc — how do they compare? Eli Lilly And Co trades at $1,215.94 (market cap $1.08T), while Prologis Inc trades at $139.84 (market cap $132.57B). The key difference: Eli Lilly And Co is far larger — about 8.1× Prologis Inc's market cap, and Prologis Inc pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| LLY | PLD | |
|---|---|---|
Market Cap | $1.08T | $132.57B |
Sector | Health | Real Estate |
52-Week High | $1.24K | $149.96 |
52-Week Low | $639.43 | $104.81 |
Enterprise Value | $1.13T | $167.31B |
Dividend Yield | 0.57% | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
Prologis (PLD) trades at $139.75, up 0.74% today, with strong recent earnings beats but a bearish technical signal. The company announced a major $18.8 billion acquisition of SEGRO, expanding its European footprint, while financials show robust profitability with a 45.79% net income margin. Cash flow trends are mixed, with 2025 showing a net outflow but a projected recovery in 2026.
The outlook is positive due to strategic growth via acquisition and consistent earnings outperformance, though risks include integration challenges from the SEGRO deal and a high P/E ratio of 31.07. Analyst consensus is bullish with a $159.22 price target, suggesting significant upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
